When to Discontinue β-Blockers and Nitroglycerin in ACS and CCS
β-Blocker Discontinuation
In ACS patients with preserved LVEF ≥50%, β-blockers can be discontinued after 1-3 years of stability post-event, as contemporary evidence shows no mortality or MACE benefit in this population. 1, 2
Immediate Discontinuation Required (During Acute Phase)
β-blockers must be stopped immediately if patients develop 3:
- New or worsening heart failure symptoms
- Signs of cardiogenic shock
- Acute heart failure (Killip class II-IV)
- Evidence of low cardiac output state
- Severe bradycardia
- PR interval >0.24 seconds
- Second- or third-degree heart block without pacemaker
- Active bronchospasm
These contraindications should be reassessed after 24 hours, as initial contraindications may resolve 3.
Long-Term Discontinuation Strategy (Post-ACS)
LVEF-Stratified Approach:
LVEF ≥50% (Preserved): Discontinue after 1-3 years if stable, no other indications exist (arrhythmias, angina, refractory hypertension), and patient experiences adverse effects or polypharmacy burden 1, 2. Pooled contemporary data shows no reduction in death, MI, or heart failure (P=0.54) in this population.
LVEF 40-49% (Mildly Reduced): Continue β-blockers long-term. This group shows 25% relative risk reduction in composite endpoints (P=0.031) 2. Discontinuation should only occur with compelling contraindications.
LVEF <40% (Reduced): Never discontinue unless absolute contraindications develop. This remains a Class I indication with well-established mortality benefit 3.
Additional Factors Favoring Discontinuation:
- Significant adverse effects (fatigue, sexual dysfunction, depression)
- Polypharmacy concerns
1-3 years post-ACS with complete stability
- Heart failure with preserved ejection fraction (HFpEF) as comorbidity
- Poor adherence to other secondary prevention therapies that are more critical 1
CCS-Specific Considerations
In chronic coronary syndrome, β-blockers are recommended as initial antianginal therapy unless contraindicated 4. Discontinue if:
- Sick sinus syndrome or atrioventricular conduction disorders develop 4
- Severe peripheral artery disease with critical limb ischemia
- Uncontrolled chronic obstructive pulmonary disease with frequent exacerbations
- Symptoms adequately controlled with alternative antianginal agents
Nitroglycerin Discontinuation
Discontinue IV nitroglycerin immediately if systolic blood pressure drops below 90 mmHg or if signs of hypotension-induced end-organ hypoperfusion develop. 5
Immediate Discontinuation Required
Stop nitroglycerin if 5:
- Severe hypotension (SBP <90 mmHg or symptomatic hypotension)
- Shock develops (even with small doses)
- Paradoxical bradycardia with increased angina
- Hypertrophic cardiomyopathy (nitrates aggravate angina in this condition)
- Right ventricular infarction (volume-depleted state)
- Concomitant phosphodiesterase inhibitor use (sildenafil, tadalafil, vardenafil)
Duration of Use in ACS
IV nitroglycerin should be used for ≤24-48 hours in the acute phase 3, 6. The 2025 ACC/AHA guidelines support initial nitrate use for symptom relief but do not recommend prolonged IV administration beyond the acute stabilization period.
Transition strategy:
- Use IV nitroglycerin for immediate symptom control in first 24-48 hours
- Transition to sublingual/oral long-acting nitrates if ongoing angina
- Discontinue completely once revascularization is complete and patient is pain-free for 12-24 hours
Long-Term Nitrate Use in CCS
For chronic coronary syndrome 4:
- Short-acting nitrates: Continue indefinitely for immediate angina relief (as-needed basis)
- Long-acting nitrates: Use as add-on therapy only if symptoms inadequately controlled with β-blockers and/or calcium channel blockers
- Implement nitrate-free intervals (12 hours daily) to prevent tolerance development 5
Discontinue long-acting nitrates if:
- Symptoms adequately controlled with other antianginal agents
- Tolerance develops despite nitrate-free intervals
- Persistent headaches or hypotension limit quality of life
- Patient develops hypertrophic cardiomyopathy
Critical Pitfall to Avoid
Do not abruptly withdraw nitrates in patients on chronic high-dose therapy—this can precipitate rebound angina, acute MI, or sudden death due to true physical dependence 5. Taper gradually over 1-2 weeks if discontinuation is necessary.
Monitoring During Nitroglycerin Use
Continuous hemodynamic monitoring is mandatory during IV nitroglycerin 5:
- Blood pressure and heart rate in all patients
- Pulmonary capillary wedge pressure when appropriate
- Maintain adequate systemic blood pressure and coronary perfusion pressure
Important drug interaction: IV nitroglycerin interferes with heparin anticoagulation—guide heparin therapy with frequent aPTT measurements 5.